A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
MoneyWeek7d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Seeking Alpha14d
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...
Precision Medicine Online14d
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
stocknews19d
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharmaceutical industry with blockbuster drug potential represents a high-growth opportunity for investors seeking transformative returns. These companies invest heavily in research and ...
Nasdaq21d
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Vertex markets all of them. Its top product, Trikafta/Kaftrio, raked in sales of $10.2 billion last year. The company won U.S. Food and Drug Administration (FDA) approval in December 2024 for ...
The Globe and Mail22d
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Vertex markets all of them. Its top product, Trikafta/Kaftrio, raked in sales of $10.2 billion last year. The company won U.S. Food and Drug Administration (FDA) approval in December 2024 for Alyftrek ...